The higher osteoprotective activity of psoralidin (cas 18642-23-4) in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis
-
Add time:09/09/2019 Source:sciencedirect.com
Prenylation of bioactive natural compounds has been postulated to be able to enhance the utilization rate and affinity of the compounds with cell membranes, thus promote their bioactivities. Coumestrol, isolated from Medicago sativa, has been known as a phytoestrogen which has bone health benefits. In our previous work, psoralidin (cas 18642-23-4), a prenylated coumestrol, was proved to have a higher ability than coumestrol to promote bone formation and to attenuate resorption in vitro. However, it remains to be investigated whether psoralidin will have stronger bone health benefits than coumestrol. In the current study, psoralidin was isolated from Psoralea corylifolia L. and the osteotropic activities of coumestrol and psoralidin were compared in ovariectomized (OVX) rats. Both coumestrol and psoralidin were found to suppress OVX-induced bone loss in vivo, as shown by improved total bone mineral content (t-BMC) or density (t-BMD) and mineral apposition rate, bone biomechanical properties, microstructure and trabecular bone formation, enhanced osteogenic differentiation but suppressed adipogenic differentiation of bone marrow stromal cells (BMSCs), and activation of PI3K/Akt axis and downstream factors such as GSK3β/β-catenin and Nrf-2/HO-1. However, psoralidin was shown to have higher activities than coumestrol in the above measurements/indices. Our findings demonstrate that psoralidin, as a novel anti-osteoporosis candidate, could suppress bone loss in OVX rats and have better osteoprotective effects than coumestrol, which may be related to the presence of the isopentenyl group in psoralidin.
We also recommend Trading Suppliers and Manufacturers of psoralidin (cas 18642-23-4). Pls Click Website Link as below: cas 18642-23-4 suppliers
Prev:Original ArticleEffect and mechanism of psoralidin (cas 18642-23-4) on promoting osteogenesis and inhibiting adipogenesis
Next:psoralidin (cas 18642-23-4) suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- psoralidin (cas 18642-23-4), a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia09/28/2019
- Pharmaceutical NanotechnologyNanoencapsulation of psoralidin (cas 18642-23-4) via chitosan and Eudragit S100 for enhancement of oral bioavailability10/01/2019
- Synthesis of psoralidin (cas 18642-23-4) derivatives and their anticancer activity: first synthesis of Lespeflorin I109/27/2019
- Comparison of the in vitro metabolism of psoralidin (cas 18642-23-4) among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes09/26/2019
- RESEARCH ARTICLE: Pharmacokinetics, Pharmacodynamics and Drug Transport and MetabolismRegio- and Isoform-Specific Glucuronidation of psoralidin (cas 18642-23-4): Evaluation of 3-O-Glucuronidation as a Functional Marker for UGT1A909/25/2019
- Molecular and cellular pharmacologypsoralidin (cas 18642-23-4), a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts09/24/2019
- psoralidin (cas 18642-23-4) suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines09/10/2019
- Original ArticleEffect and mechanism of psoralidin (cas 18642-23-4) on promoting osteogenesis and inhibiting adipogenesis09/08/2019
- ReviewMechanisms explaining the efficacy of psoralidin (cas 18642-23-4) in cancer and osteoporosis, a review09/07/2019